pneumococcal disease

News

Vaxcyte's pneumococcal jab exceeds expectations

Shares in Vaxcyte have rocketed on phase 3 trial data for its pneumococcal vaccine VAX-31 that suggests it could take on rivals from Pfizer and MSD.

News

AI spots drugs that may be repurposed for priority pathogen

Researchers have used AI algorithms to sift through thousands of drug molecules and identify some with activity against problem pathogen S pneumoniae.

News

MSD takes on Pfizer's Prevnar with new Capvaxive approval

MSD has claimed new territory for pneumococcal vaccines after getting FDA approval for use of Capvaxive in vulnerable children aged two to 17.

News

Pfizer takes 25-valent Prevnar follow-up into phase 3

Pfizer has upped the ante in the increasingly competitive market for pneumococcal vaccines with new data on a 25-valent candidate.

News

Sanofi takes SK Bio-partnered pneumococcal shot into phase 3

Sanofi has moved ahead with plans to challenge Pfizer and MSD for a piece of the market for pneumococcal vaccines.

News

Vaxcyte's pneumococcal vaccine win points to Prevnar battle

Vaxcyte's new pneumococcal vaccine may only have phase 1/2 results behind it, but analysts are already predicting it could be a major competitor to rival shots from Pfizer and MSD.

Vaxcyte's pneumococcal jab exceeds expectations

AI spots drugs that may be repurposed for priority pathogen

MSD takes on Pfizer's Prevnar with new Capvaxive approval

Pfizer takes 25-valent Prevnar follow-up into phase 3

Sanofi takes SK Bio-partnered pneumococcal shot into phase 3

Vaxcyte's pneumococcal vaccine win points to Prevnar battle

Iambic prices its IPO, seeking to raise up to $160m

Discover a new era of healthcare panel engagement: Grounded ...

pneumococcal disease

Editor's Picks